Andrea Baer: Reducing Barriers to Medication Access and Adherence - A Peer-to-Peer Community-Based Approach

Presentation by Andrea Baer, MS, director of Patient Advocacy, Mended Hearts, Inc, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Related Videos

Related Content

Advertisement

July 3rd 2025

Preference for Long-Acting vs On-Demand PrEP Seen in Black Men in the US

Julia Bonavitacola

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis (PrEP) vs on-demand PrEP.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

July 1st 2025

Surgeries and Endoscopic Procedures Offer Different Benefits for MASLD

Hayden E. Klein

Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated steatotic liver disease (MASLD).

Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

Related Content

Advertisement

July 3rd 2025

Preference for Long-Acting vs On-Demand PrEP Seen in Black Men in the US

Julia Bonavitacola

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis (PrEP) vs on-demand PrEP.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

July 1st 2025

Surgeries and Endoscopic Procedures Offer Different Benefits for MASLD

Hayden E. Klein

Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated steatotic liver disease (MASLD).

Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.